secwatch.observer — SEC 8-K summary
======================================

Issuer:     BridgeBio Oncology Therapeutics, Inc. (BBOT)
CIK:        0001869105
Form:       8-K
Filed at:   2026-09-08T20:19:06+00:00
Accession:  0001193125-26-385225
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BBOT reports 75% ORR for BBO-8520 combo in 2L+ NSCLC; focuses on KRAS combos
----------------------------------------------------------------------------

- BBO-8520 + pembrolizumab: 75% ORR at 500 mg QD, 53% across doses in 2L+ G12C inhibitor-experienced NSCLC (N=17).
- BBO-8520 monotherapy ORR 63% (26/41), DCR 100% (41/41), no grade 3 liver enzyme elevations in 2L+ G12C inhibitor-naive NSCLC.
- $344.1M cash as of June 30, 2026; projected runway into 2028.
- Strategic focus on BBO-8520 combo and BBO-11818/BBO-10203 combos in KRAS-mutant CRC and PDAC; data updates Q4 2026 and mid-2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1869105/000119312526385225/0001193125-26-385225-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1869105/000119312526385225/d97546d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-385225

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer